Horizon Pharma PLC (NASDAQ:HZNP) saw a significant decrease in short interest in the month of August. As of August 31st, there was short interest totalling 19,875,636 shares, a decrease of 6.6% from the August 15th total of 21,291,050 shares. Currently, 12.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 3,273,655 shares, the days-to-cover ratio is presently 6.1 days.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Profund Advisors LLC grew its stake in shares of Horizon Pharma PLC by 0.8% in the 1st quarter. Profund Advisors LLC now owns 13,508 shares of the biopharmaceutical company’s stock worth $200,000 after purchasing an additional 112 shares during the last quarter. US Bancorp DE grew its stake in shares of Horizon Pharma PLC by 1.2% in the 1st quarter. US Bancorp DE now owns 32,050 shares of the biopharmaceutical company’s stock worth $473,000 after purchasing an additional 368 shares during the last quarter. Prudential Financial Inc. grew its stake in shares of Horizon Pharma PLC by 2.6% in the 1st quarter. Prudential Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 420 shares during the last quarter. Sheaff Brock Investment Advisors LLC grew its stake in shares of Horizon Pharma PLC by 5.0% in the 2nd quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 500 shares during the last quarter. Finally, Amalgamated Bank grew its stake in shares of Horizon Pharma PLC by 4.8% in the 2nd quarter. Amalgamated Bank now owns 20,711 shares of the biopharmaceutical company’s stock worth $246,000 after purchasing an additional 943 shares during the last quarter. 82.30% of the stock is currently owned by institutional investors.

Shares of Horizon Pharma PLC (NASDAQ HZNP) opened at 12.29 on Friday. The stock has a 50 day moving average of $12.83 and a 200 day moving average of $13.07. Horizon Pharma PLC has a 52-week low of $9.45 and a 52-week high of $21.98. The firm’s market capitalization is $2.01 billion.

Horizon Pharma PLC (NASDAQ:HZNP) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported $0.41 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.12 by $0.29. The company had revenue of $289.51 million for the quarter, compared to analysts’ expectations of $237.01 million. Horizon Pharma PLC had a negative net margin of 42.40% and a positive return on equity of 22.85%. The business’s revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS. On average, analysts predict that Horizon Pharma PLC will post $1.08 EPS for the current fiscal year.

HZNP has been the topic of several recent analyst reports. BidaskClub upgraded shares of Horizon Pharma PLC from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. Cantor Fitzgerald set a $13.00 target price on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a research report on Monday, July 31st. ValuEngine lowered shares of Horizon Pharma PLC from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Jefferies Group LLC restated a “buy” rating and set a $14.00 target price on shares of Horizon Pharma PLC in a research report on Friday, July 14th. Finally, Zacks Investment Research upgraded shares of Horizon Pharma PLC from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 11th. Five analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. Horizon Pharma PLC has an average rating of “Buy” and an average target price of $18.67.

ILLEGAL ACTIVITY WARNING: “Short Interest in Horizon Pharma PLC (HZNP) Declines By 6.6%” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.dailypolitical.com/2017/09/14/short-interest-in-horizon-pharma-plc-hznp-declines-by-6-6.html.

About Horizon Pharma PLC

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.